JBCHEPHARM · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 64/100 — Quality 88 · Valuation 5 · Growth 72 · Momentum 90
| Share price | ₹2,408.90 |
| Market cap | ₹32,977 Cr |
| P/E ratio | 43.3 |
| P/B ratio | 8.4 |
| ROE | 22.3% |
| ROCE | 24.7% |
| Dividend yield | 1.24% |
| Book value | ₹243.38 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹4,148 Cr | ₹709 Cr | 27.0% |
| 2025 | ₹3,918 Cr | ₹660 Cr | 26.0% |
| 2024 | ₹3,484 Cr | ₹553 Cr | 26.0% |
| 2023 | ₹3,149 Cr | ₹410 Cr | 22.0% |
| 2022 | ₹2,424 Cr | ₹386 Cr | 22.0% |
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical